203 related articles for article (PubMed ID: 2226679)
1. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
Chao NJ; Aihara M; Blume KG; Sikic BI
Exp Hematol; 1990 Dec; 18(11):1193-8. PubMed ID: 2226679
[TBL] [Abstract][Full Text] [Related]
2. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
Kühl JS; Sikic BI; Blume KG; Chao NJ
Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
[TBL] [Abstract][Full Text] [Related]
3. Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture.
Aihara M; Sikic BI; Blume KG; Chao NJ
Exp Hematol; 1990 Sep; 18(8):940-4. PubMed ID: 2387345
[TBL] [Abstract][Full Text] [Related]
4. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
Yalowich JC; Zucali JR; Gross M; Ross WE
Cancer Res; 1985 Oct; 45(10):4921-4. PubMed ID: 3861238
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
[TBL] [Abstract][Full Text] [Related]
7. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines.
Hu XF; Martin TJ; Bell DR; de Luise M; Zalcberg JR
Cancer Res; 1990 May; 50(10):2953-7. PubMed ID: 2334897
[TBL] [Abstract][Full Text] [Related]
8. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
Miller G; Brashear T; Stone M; Fay J
Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738
[TBL] [Abstract][Full Text] [Related]
9. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.
Chang TT; Gulati S; Chou TC; Colvin M; Clarkson B
Cancer Res; 1987 Jan; 47(1):119-22. PubMed ID: 3466686
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy and verapamil to purge drug resistant leukemia cells from human bone marrow.
Cairo MS; Toy C; Sender L; Bennetts G; van de Ven C
Prog Clin Biol Res; 1990; 333():47-55. PubMed ID: 2308995
[No Abstract] [Full Text] [Related]
12. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
Deconinck E; Tamayo E; Hervé P
Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586
[TBL] [Abstract][Full Text] [Related]
13. Growth of hemopoietic cells after incubation with VP 16-213.
Schulze E; Hofmann U; Woetzel M; Helbig W
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):591-6. PubMed ID: 2480314
[TBL] [Abstract][Full Text] [Related]
14. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
[TBL] [Abstract][Full Text] [Related]
15. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
16. A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy.
Aihara M; Aihara Y; Schmidt-Wolf G; Schmidt-Wolf I; Sikic BI; Blume KG; Chao NJ
Blood; 1991 May; 77(9):2079-84. PubMed ID: 1673356
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
18. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
19. Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents.
Mivechi NF; Miyachi H; Scanlon KJ
Cancer Res; 1990 Apr; 50(7):2044-8. PubMed ID: 2317794
[TBL] [Abstract][Full Text] [Related]
20. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells.
Muller C; Goubin F; Ferrandis E; Cornil-Scharwtz I; Bailly JD; Bordier C; Bénard J; Sikic BI; Laurent G
Mol Pharmacol; 1995 Jan; 47(1):51-6. PubMed ID: 7838133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
